Compare YieldMax MSTR Option Income Strategy ETF (MSTY) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax MSTR Option Income Strategy ETF vs Zoetis Inc — how do they compare? YieldMax MSTR Option Income Strategy ETF trades at $13.6, while Zoetis Inc trades at $75.47 (market cap $31.95B). The key difference: Zoetis Inc pays a 2.78% dividend while YieldMax MSTR Option Income Strategy ETF pays none. Which is the better fit depends on your goals.
| MSTY | ZTS | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $108.80 | $156.76 |
52-Week Low | $11.55 | $71.91 |
Market Cap | — | $31.95B |
Enterprise Value | — | $39.24B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTY trades at $13.12, up 2.34% today but remains in a bearish technical trend with significant price erosion over the past six months. The ETF generates weekly distributions but has experienced substantial capital depreciation, with a $10,000 investment in January 2026 declining to approximately $6,614 by July 2026. Technical indicators show bearish momentum with resistance at $14 and support at $12, while fundamental valuation metrics remain unavailable for analysis.
The outlook remains challenging as MSTY's covered-call strategy caps upside potential while exposing investors to full downside risk. Despite high distribution yields, the structural limitations and dependence on underlying MSTR volatility create significant investment risks. Investors face uncapped losses despite regular payouts, with media coverage highlighting concerns about the ETF's long-term sustainability.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
